Comparison of extracorporeal shock wave therapy with Intra-Plaque Injection of Verapamil in the Treatment of Peyronie's Disease

Comparative study of extracorporeal shock wave therapy (ESWT) and Intra-Plaque Injection of Verapamil in the Treatment of Peyronie's Disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N169

Enrollment

Registered

2021-06-07

Start date

2021-06-04

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peyronie's disease. Induration penis plastica

Interventions

Intervention 1: In the first intervention group, for patients, verapamil with a dose of 10 mg and diluted in 10 ml of distilled water using a 10 ml syringe and a needle with a 25 gauge will be injecte

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 65 The duration of the disease is more than 12 months Diagnosis of pneumonia based on the opinion of a urologist and the presence of palpable plaque Married patients

Exclusion criteria

Exclusion criteria: Patient with calcified plaque History of penile surgery History of hypo or epispadias History of intra-plaque injection into the penis Existence of 2 lesions or lesions with non-measurable shape

Design outcomes

Primary

Measure	Time frame
The amount of pain. Timepoint: Beginning of study, end of week 16. Method of measurement: Based on Visual Pain Scale (VAS).;Erectile dysfunction. Timepoint: Beginning of study, end of week 16. Method of measurement: Based on the Erection Function Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSajad Moradi

Kermanshah University of Medical Sciences

sajad3258985952@gmail.com+98 83 3427 6306

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026